LRF Medical Advisory Board Member and Patient Program Presenter Makes Key Finding on Newer CLL Medication

image of Scott Smith, M.D., Ph.D. FACP

 

 

 

 

 

 

 

Scott Smith, M.D., Ph.D. FACP is co-author of a study that found that a newer targeted medication called ibrutinib is more effective at treating chronic lymphocytic leukemia (CLL) in some patients than the current standard therapy. Read more about the finding here on Science Daily.

Doctor Smith, professor, Division of Hematology/Oncology, Department of Medicine at Loyola Medicine and Loyola University Chicago Stritch School of Medicine, is part of the Leukemia Research Foundation’s Medical Advisory Board and has been a presenter at LRF Patient Educational Programs.


Category Tag(s): Current News